Letters and medicine recalls sent to healthcare professionals in December 2024
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.바카라 사이트¯
³¢±ð³Ù³Ù±ð°ù²õ바카라 사이트¯â¶Ä¯Â
In December 2024, the following letters were sent or provided to relevant healthcare professionals: 바카라 사이트¯Â
Medicine Recalls and Notifications바카라 사이트¯바카라 사이트¯Â
In December 2024, recalls and notifications for medicines were issued on:바카라 사이트¯바카라 사이트¯Â
Class 2 Medicines Recall: Wockhardt UK Limited, WockAIR 160 microgram/4.5 microgram, inhalation powder, EL(24)A/62. Issued 9 December 2024. Wockhardt UK Limited is recalling this batch as a precautionary measure following the identification of a low number of units which may have a defect in the 바카라 사이트˜top case바카라 사이트™ resulting in a dose not being able to be dispensed.바카라 사이트¯Â
Class 3 Medicines Recall: Kent Pharma UK, Phenoxymethylpenicillin 250mg/5ml Oral Solution Sugar Free, EL (24)A/60. Issued 3 December 2024. Kent Pharma UK is recalling a batch of phenoxymethylpenicillin 250mg/5mL oral solution sugar free due to a low phenoxymethylpenicillin assay.바카라 사이트¯Â
Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension, EL(24)A/59. Issued 2 December 2024. Rosemont Pharmaceuticals Limited has informed the MHRA that the Press-In-Bottle-Adaptor (PIBA) supplied with the batches listed above may cause the medicine to leak when attempting to withdraw a dose.바카라 사이트¯Â
Class 4 Medicines Defect Information: Brillpharma Limited, Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution, EL(24)A/61. Issued 4 December 2024. L M Manufacturing Limited has informed the MHRA that the patient information leaflet (PIL) in the cartons for the batch listed for Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution include an out of date PIL, dated July 2021.바카라 사이트¯Â
Class 4 Medicines Notification: Argenx BV, Vyvgart 1000 mg solution for injection, EL (24)A/63. Issued 19 December 2024. Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites. Only subcutaneous injection to the abdomen is permitted.바카라 사이트¯Â
MHRA Safety Update volume 18, issue 6: January 2025: 2